SG Americas Securities LLC Sells 5,076 Shares of R1 RCM Inc. (NASDAQ:RCM)

SG Americas Securities LLC cut its holdings in R1 RCM Inc. (NASDAQ:RCM) by 29.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,916 shares of the healthcare provider’s stock after selling 5,076 shares during the quarter. SG Americas Securities LLC’s holdings in R1 RCM were worth $169,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its stake in shares of R1 RCM by 4.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,154,888 shares of the healthcare provider’s stock valued at $39,624,000 after acquiring an additional 136,808 shares during the last quarter. Boston Partners increased its stake in R1 RCM by 4,976.6% in the first quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock valued at $32,784,000 after purchasing an additional 2,519,739 shares in the last quarter. First Light Asset Management LLC raised its holdings in R1 RCM by 212.8% in the first quarter. First Light Asset Management LLC now owns 2,552,325 shares of the healthcare provider’s stock worth $32,874,000 after purchasing an additional 1,736,346 shares during the period. Sea Cliff Partners Management LP grew its holdings in shares of R1 RCM by 14.3% in the 2nd quarter. Sea Cliff Partners Management LP now owns 2,437,450 shares of the healthcare provider’s stock valued at $30,614,000 after buying an additional 305,672 shares during the period. Finally, Empyrean Capital Partners LP bought a new stake in shares of R1 RCM in the 2nd quarter valued at $26,376,000. Institutional investors own 61.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on RCM. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 target price on shares of R1 RCM in a report on Monday, July 22nd. Jefferies Financial Group lowered R1 RCM from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Leerink Partners downgraded shares of R1 RCM from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $17.00 to $14.30 in a report on Thursday, August 1st. Leerink Partnrs lowered shares of R1 RCM from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $19.00 price objective on shares of R1 RCM in a research report on Friday, June 28th. Thirteen analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $15.41.

R1 RCM Stock Performance

Shares of NASDAQ RCM opened at $14.24 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a 50 day moving average price of $14.13 and a 200 day moving average price of $13.15. The stock has a market capitalization of $6.00 billion, a PE ratio of -178.00 and a beta of 0.85. R1 RCM Inc. has a 52 week low of $8.87 and a 52 week high of $15.12.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Wednesday, August 7th. The healthcare provider reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $627.90 million during the quarter, compared to the consensus estimate of $633.10 million. R1 RCM had a negative return on equity of 1.44% and a negative net margin of 1.68%. The business’s revenue was up 12.0% on a year-over-year basis. Analysts predict that R1 RCM Inc. will post -0.24 earnings per share for the current fiscal year.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.